Spyre Therapeutics (SYRE) Competitors $12.71 -0.31 (-2.38%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$12.22 -0.49 (-3.82%) As of 04/15/2025 04:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SYRE vs. AKRO, MOR, SWTX, PTGX, CPRX, MRUS, ALVO, APLS, SRRK, and CRNXShould you be buying Spyre Therapeutics stock or one of its competitors? The main competitors of Spyre Therapeutics include Akero Therapeutics (AKRO), MorphoSys (MOR), SpringWorks Therapeutics (SWTX), Protagonist Therapeutics (PTGX), Catalyst Pharmaceuticals (CPRX), Merus (MRUS), Alvotech (ALVO), Apellis Pharmaceuticals (APLS), Scholar Rock (SRRK), and Crinetics Pharmaceuticals (CRNX). These companies are all part of the "pharmaceutical products" industry. Spyre Therapeutics vs. Akero Therapeutics MorphoSys SpringWorks Therapeutics Protagonist Therapeutics Catalyst Pharmaceuticals Merus Alvotech Apellis Pharmaceuticals Scholar Rock Crinetics Pharmaceuticals Spyre Therapeutics (NASDAQ:SYRE) and Akero Therapeutics (NASDAQ:AKRO) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, valuation, profitability, earnings, risk, analyst recommendations, institutional ownership, media sentiment and dividends. Is SYRE or AKRO more profitable? Akero Therapeutics' return on equity of -32.46% beat Spyre Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Spyre TherapeuticsN/A -210.01% -44.40% Akero Therapeutics N/A -32.46%-29.83% Do analysts prefer SYRE or AKRO? Spyre Therapeutics currently has a consensus price target of $49.57, suggesting a potential upside of 290.02%. Akero Therapeutics has a consensus price target of $76.29, suggesting a potential upside of 100.33%. Given Spyre Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Spyre Therapeutics is more favorable than Akero Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spyre Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 3.20Akero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger earnings & valuation, SYRE or AKRO? Akero Therapeutics has lower revenue, but higher earnings than Spyre Therapeutics. Akero Therapeutics is trading at a lower price-to-earnings ratio than Spyre Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSpyre Therapeutics$890K860.52-$338.79M-$4.23-3.00Akero TherapeuticsN/AN/A-$151.76M-$3.75-10.15 Does the MarketBeat Community favor SYRE or AKRO? Akero Therapeutics received 96 more outperform votes than Spyre Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Spyre Therapeutics an outperform vote while only 65.36% of users gave Akero Therapeutics an outperform vote. CompanyUnderperformOutperformSpyre TherapeuticsOutperform Votes21100.00% Underperform VotesNo VotesAkero TherapeuticsOutperform Votes11765.36% Underperform Votes6234.64% Do insiders & institutionals have more ownership in SYRE or AKRO? 80.4% of Spyre Therapeutics shares are held by institutional investors. 6.2% of Spyre Therapeutics shares are held by insiders. Comparatively, 7.9% of Akero Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more risk & volatility, SYRE or AKRO? Spyre Therapeutics has a beta of 3.05, suggesting that its stock price is 205% more volatile than the S&P 500. Comparatively, Akero Therapeutics has a beta of -0.18, suggesting that its stock price is 118% less volatile than the S&P 500. Does the media refer more to SYRE or AKRO? In the previous week, Spyre Therapeutics had 4 more articles in the media than Akero Therapeutics. MarketBeat recorded 18 mentions for Spyre Therapeutics and 14 mentions for Akero Therapeutics. Akero Therapeutics' average media sentiment score of 1.04 beat Spyre Therapeutics' score of 0.88 indicating that Akero Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Akero Therapeutics 10 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummarySpyre Therapeutics beats Akero Therapeutics on 9 of the 17 factors compared between the two stocks. Remove Ads Get Spyre Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SYRE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SYRE vs. The Competition Export to ExcelMetricSpyre TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$765.87M$6.33B$5.33B$7.57BDividend YieldN/A3.24%5.11%4.32%P/E Ratio-1.706.7921.7317.82Price / Sales860.52225.96379.2094.61Price / CashN/A65.6738.1534.64Price / Book-57.775.866.464.00Net Income-$338.79M$141.86M$3.20B$247.23M7 Day Performance-4.94%4.50%2.86%1.45%1 Month Performance-29.55%-12.65%-8.55%-6.24%1 Year Performance-64.96%-11.06%10.47%0.60% Spyre Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SYRESpyre Therapeutics1.8047 of 5 stars$12.71-2.4%$49.57+290.0%-65.8%$765.87M$890,000.00-1.70100AKROAkero Therapeutics4.3059 of 5 stars$35.97-2.1%$76.29+112.1%+75.3%$2.86BN/A-9.5930Gap DownHigh Trading VolumeMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730SWTXSpringWorks Therapeutics2.0634 of 5 stars$36.99-5.4%$73.20+97.9%-11.6%$2.77B$191.59M-10.63230Positive NewsHigh Trading VolumePTGXProtagonist Therapeutics3.8055 of 5 stars$43.21-2.8%$62.56+44.8%+76.6%$2.65B$434.43M16.24120Positive NewsCPRXCatalyst Pharmaceuticals4.6031 of 5 stars$21.81-5.5%$32.29+48.0%+50.9%$2.65B$491.73M18.4880Positive NewsGap DownHigh Trading VolumeMRUSMerus2.8298 of 5 stars$37.39-1.9%$85.31+128.2%+4.7%$2.58B$36.13M-9.4737Positive NewsALVOAlvotech1.7014 of 5 stars$8.32-2.1%$18.00+116.3%-31.2%$2.51B$489.68M-4.501,026Analyst RevisionGap DownAPLSApellis Pharmaceuticals4.1187 of 5 stars$19.80-0.9%$45.59+130.2%-63.2%$2.49B$781.37M-9.75770Gap DownSRRKScholar Rock3.8738 of 5 stars$26.04-3.2%$42.67+63.9%+126.7%$2.47B$33.19M-11.08140Positive NewsCRNXCrinetics Pharmaceuticals3.6081 of 5 stars$26.38-1.9%$73.00+176.7%-32.1%$2.45B$1.04M-7.07210Positive News Remove Ads Related Companies and Tools Related Companies AKRO Competitors MOR Competitors SWTX Competitors PTGX Competitors CPRX Competitors MRUS Competitors ALVO Competitors APLS Competitors SRRK Competitors CRNX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SYRE) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredThis story is about to go viralThis Story Could Go Viral as Soon as May 31 Quietly, towns like Shreveport, Louisiana and Fort Worth, Texas...Stansberry Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spyre Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spyre Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SYRE Stock Free SYRE Stock Alerts